HitGen, Inc. Hits Day Low at CNY 29.00 Amid Price Pressure

HitGen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 3.93% on February 24, 2026, reaching an intraday low of CNY 29.00. This performance comes amid a broader market context where the China Shanghai Composite index fell by 1.26% on the same day. Over the past week, HitGen has seen a decrease of 2.58%, contrasting with a slight gain of 0.41% in the Shanghai Composite. The stock's performance over the past month has been more pronounced, with a decline of 22.48%, while the index itself has only dipped by 1.37%. However, looking at a longer timeframe, HitGen has shown resilience, boasting an impressive 89.63% increase over the past year, significantly outperforming the Shanghai Composite's 22.49% gain. Financially, HitGen reported a remarkable net profit growth of 114.98% as of September 25, alongside a robust operating cash flow of CNY 204.8 million. The company maintains a market capitalization of CNY 11,800 million and a price-to-earnings ratio of 78.00, reflecting its position in the market.